Protagonist Therapeutics Inc (PTGX) - Total Liabilities
Based on the latest financial reports, Protagonist Therapeutics Inc (PTGX) has total liabilities worth $56.25 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Protagonist Therapeutics Inc to assess how effectively this company generates cash.
Protagonist Therapeutics Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Protagonist Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Protagonist Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Protagonist Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Protagonist Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ServiceTitan, Inc. Class A Common Stock
NASDAQ:TTAN
|
USA | $219.82 Million |
|
Lagercrantz Group AB (publ)
ST:LAGR-B
|
Sweden | Skr8.52 Billion |
|
ShenZhen YUTO Packaging Technology Co Ltd
SHE:002831
|
China | CN¥10.67 Billion |
|
OHB SE
XETRA:OHB
|
Germany | €1.12 Billion |
|
Imeik Technology Development Co
SHE:300896
|
China | CN¥743.43 Million |
|
COSCO SHIPPING Holdings Co. Ltd
F:C6G
|
Germany | €215.60 Billion |
|
Macy’s Inc
NYSE:M
|
USA | $11.38 Billion |
|
SIGMASTAR TECH LTD
SHE:301536
|
China | CN¥1.53 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Protagonist Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Protagonist Therapeutics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protagonist Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual total liabilities of Protagonist Therapeutics Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $69.43 Million | +226.36% |
| 2023-12-31 | $21.27 Million | -34.18% |
| 2022-12-31 | $32.32 Million | -32.21% |
| 2021-12-31 | $47.67 Million | +6.27% |
| 2020-12-31 | $44.86 Million | -40.15% |
| 2019-12-31 | $74.95 Million | +178.05% |
| 2018-12-31 | $26.96 Million | -37.46% |
| 2017-12-31 | $43.10 Million | +569.81% |
| 2016-12-31 | $6.43 Million | +22.59% |
| 2015-12-31 | $5.25 Million | +121.20% |
| 2014-12-31 | $2.37 Million | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more